Rocket Pharmaceuticals, Inc. Finance Lease, Liability, to be Paid, Year Two
Rocket Pharmaceuticals, Inc. (RCKT) had Finance Lease, Liability, to be Paid, Year Two of $2.03 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Commitment and Contingencies › Finance Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo · last filed 2026-08-10
- 2026-06-30: Finance Lease, Liability, to be Paid, Year Two $2.03M.
- 2026-03-31: Finance Lease, Liability, to be Paid, Year Two $2.03M.
- 2025-12-31: Finance Lease, Liability, to be Paid, Year Two $2.15M.
- 2025-09-30: Finance Lease, Liability, to be Paid, Year Two $1.97M.
| Period end | Finance Lease, Liability, to be Paid, Year Two |
|---|---|
| 2026-06-30 | $2.03M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $2.03M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $2.15M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.97M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $1.97M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $1.97M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $1.91M 10-K · filed 2025-02-27 |
| 2024-09-30 | $1.91M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $1.91M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $1.91M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $1.86M 10-K · filed 2024-02-27 |
| 2023-09-30 | $1.86M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $1.86M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $1.86M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $1.79M 10-K · filed 2023-02-28 |
| 2022-09-30 | $1.79M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $1.79M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $1.79M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $1.74M 10-K · filed 2022-02-28 |
| 2021-09-30 | $1.74M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $1.74M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $1.74M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $1.69M 10-K · filed 2021-03-01 |
| 2020-09-30 | $1.69M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $1.69M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $1.69M 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |